Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge

1. U.S. District Court denied FTC's injunction against Surmodics' acquisition by GTCR. 2. The merger valued Surmodics at $627 million, or $43 per share. 3. Surmodics shares increased 49.93%, reaching a new 52-week high. 4. Surmodics remains confident the merger will benefit all stakeholders. 5. FTC previously challenged GTCR's investment in Biocoat, raising competitive concerns.